The European Association of Urology 2024 (EAU24) is Europe’s largest Annual Urology Congress which took place on April 5-8, in Paris, France.
We have selected three bladder cancer research studies presented at EAU24, with lay summaries of each study provided below.
Localised chemotherapy for people with high-risk, non-muscle-invasive bladder cancer
The SunRISe-1 study is evaluating the effectiveness and safety of TAR-200, a new treatment for people with high-risk non-muscle-invasive bladder cancer who found that standard BCG treatment didn’t work for them and who are unable to have surgery (cystectomy).



